



Active Bacterial Core Surveillance (ABCs) Report

Emerging Infections Program Network

Neisseria meningitidis, 1999



ABCs Areas

California (3 county San Francisco Bay area); Connecticut; Georgia; Maryland; Minnesota; New York (15 county Rochester/Albany area); Oregon; Tennessee (5 urban counties)

ABCs Population

The surveillance areas represent 31,711,122 persons.
Source: U.S. Bureau of the Census, 1999

ABCs Case Definition

Invasive meningococcal disease: isolation of *Neisseria meningitidis* from normally sterile site in a resident of a surveillance area in 1999.

ABCs Methodology

Project personnel communicated at least monthly with contacts in all microbiology laboratories serving acute care hospitals in their area to identify cases. Standardized case report forms that include information on demographic characteristics, clinical syndrome, and outcome of illness were completed for each identified case. Molecular subtyping was done on meningococcal isolates at CDC. Regular laboratory audits assess completeness of active surveillance and detect additional cases.

All rates of invasive meningococcal disease were calculated using U.S. Bureau of the Census postcensal population estimates for 1999.

For national projections of cases, race- and age-specific rates of disease were applied from the aggregate surveillance area to the age and racial distribution of the 1999 U.S. population.

Cases with unknown race were distributed by area based on reported race distribution for known cases within the eight age categories.

Reported ABCs Profiles

Race	No. (Rate*)
White	247 (1.0)
Black	85 (1.6)
Other	15 (0.9)
Total	347 (1.1)

Unknown race (n=40) distributed among knowns

*Cases per 100,000 population for ABCs areas.

Syndrome	Cases		Deaths	
	No.	(%*)	No.	(Rate [†])
Meningitis	162	(46.7)	17	(10.5)
Bacteremia w/o focus	139	(40.1)	18	(12.9)

*Percent of cases. †Deaths per 100 cases with known outcome

Age (years)	Serogroups									
	B		C		Y		Other			
	No.	(Rate*)	No.	(Rate)	No.	(Rate)	No.	(Rate)	No.	(Rate)
<1	26	(6.0)	8	(1.8)	16	(3.7)	4	(0.9)		
1	4	(0.9)	2	(0.5)	2	(0.5)	1	(0.2)		
2-4	15	(1.2)	12	(0.9)	3	(0.2)	4	(0.3)		
5-17	15	(0.3)	28	(0.5)	18	(0.3)	3	(0.1)		
18-34	23	(0.3)	26	(0.3)	17	(0.2)	7	(0.1)		
35-49	11	(0.1)	6	(0.1)	14	(0.2)	7	(0.1)		
50-64	6	(0.1)	2	(0.04)	11	(0.2)	6	(0.1)		
≥65	8	(0.2)	7	(0.2)	25	(0.7)	10	(0.3)		
Total	108	(0.3)	91	(0.3)	106	(0.3)	42	(0.1)		

* Cases per 100,000 population for ABCs areas

Serogroup B Isolates						
Serosubtypes	No. (%)		Serotypes:		No. (%)	
	No.	(%)	Serosubtype	No.	(%)	
P1.7,16	12	24	15:P1.7,16	11	22	
P1.22a,14	9	18	NT:P1.22a,14	6	12	
P1.4	4	8	2A:P1.5,2	3	6	
P1.5,2	4	8	4,7:P1.4	3	6	
P1.6	3	6	14:NT	2	4	
P1.7,1	3	6	4,7:P1.7,1	2	4	

*OR isolates not included due to continuing increase of P1.7,16

National Projection for Invasive Disease:

Cases: 2,957 (1.1/100,000)

Deaths: 316 (0.1/100,000)

Healthy People 2010 Update:

Objective: Reduce the incidence of invasive meningococcal disease to 0.9 per 100,000 population.

2010 Objective	1999 Rate*
0.9/100,000	1.1

*Cases per 100,000 U.S. population.

Source: ABCs/NETSS

For more information, visit our web site at:

<http://www.cdc.gov/abc>